The Head and Neck Oncology Program (HNOP) is a comprehensive program in head and neck cancer research that includes a multidisciplinary team of Investigators In basic, clinical, behavioral, population and translational research. The program consists of 44 members from 11 departments in five schools across the University of Michigan. The HNOP's direct cost funding has increased by 60% over this grant period, to over $5 million of which $2 is in NCI funding, including a Head and Neck SPORE. Program members published 293 papers during this grant period, 22.5% of which demonstrated intra-programmatic and 33.4% Inter-programmatic collaborations. Many members of this program also hold joint membership in other Cancer Center basic science or prevention programs which integrate additional fundamental research into the underlying mechanisms of head and neck cancer behavior and treatment. The major research themes of the HNOP are to; 1. Identify mechanisms of carcinogenesis and progression 2. Determine the molecular determinants of treatment response 3. Characterize the immunobiology of the tumor microenvironment to better modulate the immune system as a therapeutic modality 4. Characterize the role of cancer stem cells in tumor progression, Invasion, metastasis and resistance to treatment 5. Define new treatment combinations based on laboratory and clinical studies that define new biomarkers for individualized therapies 6. Define organ preservation strategies in head and neck cancer 7. Develop and implement novel reconstruction and rehabilitation techniques for head and neck cancer patients This program has undergone considerable recruitment over this grant period with 18 new faculty members, and a renewed/expanded emphasis on translational research that should become fully realized over the next grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-25
Application #
8559859
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
25
Fiscal Year
2013
Total Cost
$81,662
Indirect Cost
$34,428
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Harvey, Innocence; Stephenson, Erin J; Redd, JeAnna R et al. (2018) Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. Endocrinology 159:2275-2287
Schuetze, Scott M; Bolejack, Vanessa; Thomas, Dafydd G et al. (2018) Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 4:814-820
Wagner, Vivian P; Martins, Manoela D; Martins, Marco A T et al. (2018) Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep 8:2065
Hosoya, Tomonori; D'Oliveira Albanus, Ricardo; Hensley, John et al. (2018) Global dynamics of stage-specific transcription factor binding during thymocyte development. Sci Rep 8:5605
Schofield, Heather K; Tandon, Manuj; Park, Min-Jung et al. (2018) Pancreatic HIF2? Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. Cell Mol Gastroenterol Hepatol 5:169-185.e2
Su, Wenmei; Feng, Shumei; Chen, Xiuyuan et al. (2018) Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. Cancer Res 78:3207-3219
Moody, Rebecca Reed; Lo, Miao-Chia; Meagher, Jennifer L et al. (2018) Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem 293:2125-2136
Ma, Vincent T; Boonstra, Philip S; Menghrajani, Kamal et al. (2018) Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clin Lymphoma Myeloma Leuk 18:e201-e210
Collins, Dalis; Fry, Christopher; Moore, Bethany B et al. (2018) Phagocytosis by Fibrocytes as a Mechanism to Decrease Bacterial Burden and Increase Survival in Sepsis. Shock :
Wang, Xuexiang; Dande, Ranadheer R; Yu, Hao et al. (2018) TRPC5 Does Not Cause or Aggravate Glomerular Disease. J Am Soc Nephrol 29:409-415

Showing the most recent 10 out of 1493 publications